AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Drug delivery firm reports 79% increase in revenues.
2003 AUG 29 - (NewsRx.com & NewsRx.net) -- Cima Labs, Inc., (CIMA) reported record results for the second quarter ended June 30, 2003.
Highlights include the following:
1) Revenues increased 79% year-over-year to $18.3 million, from $10.2 million in the second quarter of 2002, and rose 10%sequentially from $16.7 million in the first quarter of 2003.
2) Operating income was $4.2 million (23.2% of revenue), a 117%increase from the second quarter of 2002. In addition, CIMA's operating income increased 10% sequentially from $3.9 million(23.2% of revenues) in the first quarter of 2003, despite higher-than-anticipated legal costs associated with a patent defense claim.
3) Other income, principally investment income, declined approximately 56% year-over-year to $849,000 in the second quarter of 2003 due to lower reinvestment rates.
- CIMA LABS Announces Record Results for First Quarter of 2003; Revenues Nearly...
- Press release article from: Business Wire May 1, 2003 700+ words
...of Alavert and Remeron SolTabs, our business...CIMA's first-quarter 2003 pre-tax...s shipments of Remeron SolTabs, our partner Organon...high in the first quarter of 2003, reflecting...sequentially. "First-quarter sales benefited from the strength of Remeron ...
- Drug delivery firm reports 79% increase in revenues.
- Newspaper article from: Biotech Week August 27, 2003 700+ words
...during the second quarter, as our sales of Remeron SolTabs and Alavert to CIMA...million in the second quarter of 2003," said...financial officer. "Remeron SolTabs and Alavert dominated...production mix during the quarter." "Product development...
- CIMA LABS Announces Third-Quarter 2003 Financial Results; Product Sales More...
- Press release article from: Business Wire October 30, 2003 700+ words
...end of our third-quarter guidance range for revenue on strong sales of Remeron SolTabs and Alavert to our...doubled from the third quarter a year ago." "Wyeth...eclipsed Organon's Remeron SolTabs to become CIMA's...contributor in the third quarter," said Ratoff...
- Product sales double, royalties up 76% for antihistamine maker.
- Newspaper article from: Drug Week November 28, 2003 700+ words
...end of our third-quarter guidance range for revenue on strong sales of Remeron SolTabs and Alavert to our...doubled from the third quarter a year ago." "Wyeth...eclipsed Organon's Remeron SolTabs to become Cima's...contributor in the third quarter," said Ratoff...
- CIMA LABS Announces First-Quarter Financial Results; Patient Enrollment Begins...
- Press release article from: Business Wire May 6, 2004 700+ words
...sequential fourth quarter of 2003. CIMA...results for the first quarter of 2004 with results for prior quarters. Within this news...well in the first quarter," said Steven...Organon's Remeron SolTabs and AstraZeneca...
- Barr Receives Tentative Approval for Mirtazapine Orally Disintegrating Tablets,...
- Press release article from: PR Newswire January 7, 2005 700+ words
...exclusivities surrounding this product. Mirtazapine Orally Disintegrating Tablets are indicated for the treatment of depression. Remeron Soltabs, 45 mg had annual sales of approximately $17 million for the twelve months ended November 2004, based on IMS data. Barr...
- CIMA LABS Announces Fourth-Quarter and Full-Year 2003 Financial Results;...
- Press release article from: Business Wire February 26, 2004 700+ words
...results for prior quarters. Within this news...seventh consecutive quarter of record revenues...Fentanyl. For the quarter, Organon's Remeron SolTabs, Wyeth's Alavert...Our fourth-quarter pipeline and business...
- Cephalon, Inc. Appoints Dr. Raj Khankari as General Manager of CIMA LABS.
- Press release article from: PR Newswire December 4, 2006 700+ words
...development and launch of partner products such as Wyeth's Alavert(R), AstraZeneca's Zomig(R) ZMT, Organon's Remeron Soltabs(R) Novartis' Triaminic(R) Softchews, and the newest Cephalon product, FENTORA(TM) (fentanyl buccal tablet...